104 related articles for article (PubMed ID: 11669508)
41. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
42. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis F
Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
[TBL] [Abstract][Full Text] [Related]
43. [Acetylcholinesterase inhibitors for dementia--an update].
Anghelescu I; Heuser I
MMW Fortschr Med; 2007 May; 149 Suppl 2():76-8. PubMed ID: 17724973
[TBL] [Abstract][Full Text] [Related]
44. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
[TBL] [Abstract][Full Text] [Related]
45. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.
Seltzer B
J Int Med Res; 2006; 34(4):339-47. PubMed ID: 16989488
[TBL] [Abstract][Full Text] [Related]
46. [Galanthamine versus donepezil in the treatment of Alzheimer's disease].
López-Pousa S; Garre-Olmo J; Vilalta-Franch J
Rev Neurol; 2007 Jun 1-15; 44(11):677-84. PubMed ID: 17557224
[TBL] [Abstract][Full Text] [Related]
47. Cholinesterase inhibitors stabilize Alzheimer's disease.
Giacobini E
Ann N Y Acad Sci; 2000; 920():321-7. PubMed ID: 11193171
[TBL] [Abstract][Full Text] [Related]
48. [Pharmacotherapy for Alzheimer's disease].
Verhey FR
Tijdschr Psychiatr; 2006; 48(1):17-26. PubMed ID: 16955982
[TBL] [Abstract][Full Text] [Related]
49. Evidence-based pharmacotherapy of Alzheimer's disease.
Evans JG; Wilcock G; Birks J
Int J Neuropsychopharmacol; 2004 Sep; 7(3):351-69. PubMed ID: 15228642
[TBL] [Abstract][Full Text] [Related]
50. Treatment of Alzheimer's disease in the long-term-care setting.
Smith DA
Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
[TBL] [Abstract][Full Text] [Related]
51. Effective pharmacological management of Alzheimer's disease.
Atri A
Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
[TBL] [Abstract][Full Text] [Related]
52. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Prasher VP
Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
[TBL] [Abstract][Full Text] [Related]
53. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
[TBL] [Abstract][Full Text] [Related]
54. Diagnosis and treatment of dementia with Lewy bodies.
Josif S; Graham K
JAAPA; 2008 May; 21(5):22-6. PubMed ID: 18556885
[No Abstract] [Full Text] [Related]
55. Current and emerging pharmacological treatment options for dementia.
Ringman JM; Cummings JL
Behav Neurol; 2006; 17(1):5-16. PubMed ID: 16720956
[TBL] [Abstract][Full Text] [Related]
56. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
Gauthier S; Emre M; Farlow MR; Bullock R; Grossberg GT; Potkin SG
Curr Med Res Opin; 2003; 19(8):707-14. PubMed ID: 14687441
[TBL] [Abstract][Full Text] [Related]
57. Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Doody RS
J Clin Psychiatry; 2003; 64 Suppl 9():11-7. PubMed ID: 12934969
[TBL] [Abstract][Full Text] [Related]
58. A clinical overview of cholinesterase inhibitors in Alzheimer's disease.
Farlow M
Int Psychogeriatr; 2002; 14 Suppl 1():93-126. PubMed ID: 12636182
[TBL] [Abstract][Full Text] [Related]
59. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Rösler M
Int J Clin Pract Suppl; 2002 Jun; (127):20-36. PubMed ID: 12139365
[TBL] [Abstract][Full Text] [Related]
60. Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.
Aisen PS
J Am Acad Nurse Pract; 2005 Mar; Suppl():5-7. PubMed ID: 16033023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]